Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

NCT00661713 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1631

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: rMenB+OMV NZ
BIOLOGICAL: Placebo

Sponsor

Novartis Vaccines